29th Mar 2006 10:53
Sinclair Pharma PLC29 March 2006 Sinclair Pharma plc ("the Company") Result of EGM London, 29 March 2006 - At the extraordinary general meeting ("EGM") of theCompany held earlier today, the two resolutions put to shareholders were dulypassed, approving the increase to the authorised share capital of the Company,and authorising the Directors to allot the shares to be issued pursuant to thevendor placing in respect of the acquisition of Groupe CS Dermatologie SAS,announced on 13 March 2006 (the "Vendor Placing"). The 28,000,000 new Ordinary Shares of 1 pence each in the Company to be issuedin the Vendor Placing at a price of 125 pence per share will be admitted totrading on AIM tomorrow, 30 March 2006. Following admission of the new OrdinaryShares to trading on AIM, there will be 93,276,219 Ordinary Shares in theCompany in issue. Full details of the Vendor Placing and the acquisition are set out in theshareholder circular published on 13 March 2006. Further information: Sinclair Pharma plc +44 (0)1483 426 644Dr Michael FlynnJerry Randall Piper Jaffray Ltd. +44 (0) 20 7743 8700David RasoulyJamie Adams Financial Dynamics +44 (0)20 7831 3113Ben Atwell Piper Jaffray Ltd. is nominated adviser and joint broker to the Company for thepurpose of the AIM Rules. Piper Jaffray Ltd., which is authorised and regulatedin the United Kingdom by the Financial Services Authority and is a member of theLondon Stock Exchange, is acting exclusively for the Company in relation to theVendor Placing and the Acquisition. Piper Jaffray Ltd. is not acting for anyother person in connection with the matters referred to in this announcement andwill not be responsible to anyone other than the Company for providing theprotections afforded to clients of Piper Jaffray Ltd. or for giving advice inrelation to the matters referred to in this announcement. This announcement does not constitute or form part of any offer to sell or issueor the solicitation of any offers to purchase or subscribe for new ordinaryshares in any jurisdiction. This announcement is not an offer of securities forsale in the United States. The new ordinary shares to be issued have not beenand will not be registered under the United States Securities Act of 1933 (asamended) (the "Securities Act") or the securities laws of any state or otherjurisdiction of the United States and new Ordinary Shares may not be offered orsold, direct or indirect through CREST or otherwise within the United States,absent registration under the Securities Act or an exemption from registration.No public offer of new ordinary shares is being registered in the United States. This announcement does not constitute or form part of any offer or invitation tosell or issue, or any solicitation of any offer to purchase or subscribe for,any securities other than the securities to which it relates or any offer orinvitation to sell or issue, or any solicitation of any offer to purchase orsubscribe for, such securities by any person in any circumstances, and in anyjurisdiction, in which such offer or solicitation is unlawful. Accordingly,copies of this announcement are not being and must not be mailed or otherwisedistributed or sent in or into or from the United States, Canada, Australia orJapan and any person receiving this announcement (including custodians, nomineesand trustees) must not distribute or send it in or into or from the UnitedStates, Canada, Australia or Japan. Neither the delivery of this announcement nor any subscription or sale madeunder it shall, under any circumstances, create any implication that there hasbeen no change in the affairs of the Group since the date of this announcementor that the information in it is correct as of any subsequent time. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma